Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
Bhupendra Khatri(Hope Center for Neurological Disorders), Jeffrey A. Cohen(Cleveland Clinic), Tracy Stites, Jean Pelletier(Hôpital de la Timone), Ludwig Kappos(University Hospital of Basel), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Stacy Wu, Fred Holdbrook(Novartis (United States)), Giancarlo Comi(Vita-Salute San Raffaele University), Hans-Peter Hartung(The University of Sydney), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Gordon Francis(Novartis (United States)), Lixin Zhang-Auberson(Novartis (Switzerland))
Cited by 216
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k